[
  {
    "ts": "2026-01-12T15:18:07+00:00",
    "headline": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
    "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
    "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
      "content": {
        "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
        "contentType": "STORY",
        "title": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
        "description": "",
        "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
        "pubDate": "2026-01-12T15:18:07Z",
        "displayTime": "2026-01-12T15:18:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/46871d11-8f1b-3c57-8fe7-97bc22a117a0/jpm-preannouncements-take.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zH7azFdDXv8e5vYEYm7z1Q--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XpSqX7kq1txWcXI3OMAMZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "APLS"
            },
            {
              "symbol": "DAWN"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IONS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T14:41:00+00:00",
    "headline": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
    "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
    "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b012d38a-caa6-3035-a669-9b3231946424",
      "content": {
        "id": "b012d38a-caa6-3035-a669-9b3231946424",
        "contentType": "STORY",
        "title": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
        "description": "",
        "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
        "pubDate": "2026-01-12T14:41:00Z",
        "displayTime": "2026-01-12T14:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T11:24:00+00:00",
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
      "content": {
        "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
        "contentType": "STORY",
        "title": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
        "description": "",
        "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
        "pubDate": "2026-01-12T11:24:00Z",
        "displayTime": "2026-01-12T11:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-buys-pd-1-vegf-112400265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BEAM"
            },
            {
              "symbol": "ATRA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T16:38:00+00:00",
    "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
    "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
    "url": "https://www.barrons.com/articles/biotech-stocks-chase-conference-b9cab762?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b75019f7-5087-30b3-a925-6f9de1cc8a35",
      "content": {
        "id": "b75019f7-5087-30b3-a925-6f9de1cc8a35",
        "contentType": "STORY",
        "title": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
        "description": "",
        "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
        "pubDate": "2026-01-12T16:38:00Z",
        "displayTime": "2026-01-12T16:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b75019f7-5087-30b3-a925-6f9de1cc8a35/%E2%80%98biotech-super-bowl%E2%80%99-lands.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BHJPDjWZKaPfXg5a3nUTWQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qa7w9DeR_tRxUp5wVzRzPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stocks-chase-conference-b9cab762?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "XBI"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]